Karyotype of Leukemia Cells Consistently Predicts for Response to Therapy and Survival Following Salvage Therapy in Acute Myeloblastic Leukemia
Following the introduction of anthracyclines and cytosine arabinoside (Ara-C) into clinical practice in the late 1960s, response rates of 50%–80% in previously untreated patients with acute myeloblasts leukemia (AML) have been obtained [1, 2]. Despite a variety of postremission treatments the remission duration remains 12–15 months, with 20%–25% of patients staying in long-term disease-free state and possibly being cured [3, 4]. One-third of the patients who failed to achieve an initial complete remission do so because of persistence of leukemia cells , and 75%–80% of patients who achieve a remission have recurrence of leukemia [3, 4]. Both of these patient populations are eligible for salvage therapy.
KeywordsAcute Leukemia Salvage Therapy Cytosine Arabinoside Acute Myeloblastic Leukemia Remission Duration
Unable to display preview. Download preview PDF.
- 1.Keating MJ, Smith TL, McCredie KB, Bodey GP, Hersh EM, Gutterman JU, Gehan EA, Freireich EJ (1981) A four-year experience with anthracycline, cytosine arabinoside, vincristine, and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47: 2779 - 2788PubMedCrossRefGoogle Scholar
- 2.Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawahi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, Ellison RR, Kung F, Henry P, Mclntyre OR, Kaan SK (1981) Treatment of myelocytic leukaemia. A study by Cancer and Leukaemia Group B. Blood 58: 1203-1212Google Scholar
- 4.Weinstein HM, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD (1983) Chemotherapy for acute myelogenous leukemia in children and adults. VAPA update. Blood 62: 315-319Google Scholar
- 10.Benjamin RS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1977) Phase I-II trial of rubidazone in patients with acute leukemia. Cancer Res 37: 4223 - 4228Google Scholar
- 11.Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW (1985) Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin ( Idarubicin) in adult patients with acute leukemia. Cancer Res 45: 1408-1412Google Scholar
- 12.Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters RS, Kantarjian HM; Andersson BS, Beran M, McCredie KB, Freireich EJ (1985) Evolution of clinical studies with high-dose cytosine arabinoside at the M. D. Anderson Hospital. Semin Oncol 12: 98-104Google Scholar
- 13.Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, Mcintosh S (1979) High dose cytosine arabinoside ( HDARAC) in refractory acute leukemia. Cancer 44: 1189-1193Google Scholar
- 16.Bennett JM, Lymann GH, Cassileth PA, Glick JH, Oken MM (1984) A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group Study. Am J Clin Oncol 7: 471-473Google Scholar
- 20.Smith TL, Gehan EA, Keating MJ, Freireich EJ (1982) Prediction of remission in adult acute leukemia. Development and testing of predictive models. Cancer 50: 466-471Google Scholar